Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease
| Autor: | Jianquan Zhang, Li-Mei Ou, Jingmin Deng, Jing Bai, Guangnan Liu, Mei-Hua Li, William MacNee, Xiaoning Zhong, Zhiyi He |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Sputum Cytology medicine.drug_class Antibiotics Erythromycin Inflammation Gastroenterology Leukocyte Count Pulmonary Disease Chronic Obstructive Double-Blind Method Internal medicine medicine Humans Antibacterial agent Aged COPD business.industry Respiratory disease Sputum respiratory system Middle Aged medicine.disease Anti-Bacterial Agents respiratory tract diseases Treatment Outcome Immunology Quality of Life Female medicine.symptom business Leukocyte Elastase medicine.drug |
| Zdroj: | He, Z-Y, Ou, L-M, Zhang, J-Q, Bai, J, Liu, G-N, Li, M-H, Deng, J-M, MacNee, W & Zhong, X-N 2010, ' Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease ', Respiration, vol. 80, no. 6, pp. 445-452 . https://doi.org/10.1159/000321374 |
| Popis: | Background: Chronic obstructive pulmonary disease (COPD) is characterized by airway inflammation and is associated with acute exacerbations. Macrolide antibiotics have been shown to exhibit anti-inflammatory effects in some chronic airway inflammatory diseases. Objective: The aim of this study was to assess the effect of treatment with erythromycin on airway inflammation and health outcome in COPD patients. Methods: We conducted a randomized, placebo-controlled, double-blind trial of erythromycin for a period of 6 months. Thirty-six COPD patients were randomized to treatment with oral erythromycin (125 mg, three times/day) or placebo. The primary outcomes were neutrophil number in sputum and exacerbations. Results: Thirty-one patients completed the study. At the end of treatment, neutrophil counts in the sputum were significantly decreased in the group treated with erythromycin compared with placebo-treated patients (p = 0.005). Total cells in the sputum and neutrophil elastase in sputum supernatant were also significantly decreased in those treated with erythromycin compared with the placebo group (p = 0.021 and p = 0.024, respectively). The mean exacerbation rate was lower in the erythromycin group than in the placebo group (relative risk = 0.554, p = 0.042). Kaplan-Meier survival analysis showed that erythromycin significantly delayed the time to the first COPD exacerbation compared with placebo (p = 0.032). Conclusions: Erythromycin treatment in COPD patients can reduce airway inflammation and decrease exacerbations and may therefore be useful in the management of COPD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|